This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Care Winners and Losers: Boston Scientific

(Updated with final closing prices)

Shares of companies that make heart devices mostly traded higher Tuesday, after Boston Scientific (BSX - Get Report) reported successful trial results for one of its products, which analysts said could lead to better sales of other items.

Boston Scientific said its device designed to re-coordinate the pumping of the right and left ventricles, called a cardiac resynchronization therapy defibrillator, reduced death and the need for hospitalization in heart failure patients. Boston Scientific said its device was more effective than traditional implantable cardioverter defibrillators.

The devices deliver electric shocks to the heart to restore a normal rhythm. Use of implantable heart devices has slumped in recent years because of product recalls and safety concerns.

"There is no question that the penetration of CRT-D devices will increase," said Jefferies analyst Peter Bye, because the trial data could lead to expanded health insurance and Medicare coverage for implants. However, he said, it's not clear how many more patients will be considered good candidates for the implants.

Boston Scientific shares rose 27 cents, or 2.9%, to close at $9.51. Shares of St. Jude Medical (STJ - Get Report), a company Bye singled out as a beneficiary of improved sales, added $1.01, or 2.6%, to $40.55.

Elsewhere, shares of Abbott Laboratories (ABT - Get Report) gained 15 cents to $46.86 and Medtronic's (MDT - Get Report) stock gained 18 cents, to $33.37.

Shares of Johnson & Johnson (JNJ - Get Report) slipped 48 cents to $55.01.

Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ABT $46.25 0.00%
BSX $18.40 0.00%
JNJ $99.58 0.00%
MDT $76.49 0.00%
STJ $67.76 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs